Enhertu an Anti – Cancer Drug

What is Enhertu ?

Enhertu (Fam-trastuzumab deruxtecan-nxki) is used in chemotherapy as a chemo drug and also for Anti – Cancer targeted therapy as an anti cancer drug . 

Enhertu side effects: The most commonly reported side effects of Enhertu are:

• cough
• nausea
• vomiting
• fatigue
• hair loss
• constipation
• anemia
• diarrhea
• decreased appetite
• low white blood cell counts

This medicine also can cause some serious side effects. While these serious effects are less common, it’s crucial to know about them:

Heart problems: Enhertu may be responsible for causing serious heart complications, including a few that don’t have signs/symptoms, such as reduced heart function, and a few that do have signs/symptoms, such as congestive heart failure. Signs/symptoms to monitor for include shortness of breath, swelling of the ankles or legs, cough, or weight gain of more than five pounds in less than 24 hours.

Interstitial lung disease: Interstitial lung disease (ILD) is a general term for such disorders that are responsible for causing inflammation and scarring in the lungs. The scarring makes lung tissue stiff, which makes it tough to breathe. Patients should be precisely monitored for signs of ILD while on treatment with Enhertu and inform your health specialist right away in case you have a dry cough or experience shortness of breath. 

How Enhertu helps in fighting Cancer?

Trastuzumab the antibody part targets and gets attached to the Her2 receptor of the cancer cells . Once the Trastuzumab is attached the chemotherapy part 

(deruxtecan) gets released in the cancer cells and destroys the cancer cells and other surrounding cancer cells . 

What are the ingredients in Enhertu? 

fam-trastuzumab deruxtecan-nxki is the active ingredient in Enhertu and inactive ingredient includes L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and sucrose. 

Can you Explain the Trastuzumab and Deruxtecan section of Enhertu in a better way ? 

Yes , Enhertu has been made in combination of 2 different cancer drugs that are Trastuzumab section which is a targeted therapy and designed for find and target the Her2 receptor on cancer cells and Deruxtecan section which destroys the cancer cells after it has been targeted . So it is made by two drugs by joining two different ADC ( Antibody -drug conjugate ) . 

Is enhertu for breast cancer

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer. Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer.

What is dosage form and strength of Enhertu ? Please also tell how it can be taken . 

Enhertu is supplied as an injection of 100 mg lyophilized powder in a single-dose vial , normally given as an IV (intravenous) infusion once enery 3 weeks , still we would suggest to ask a authorised doctor before taking a specific dose of Enhertu , and please don’t take this medicine without the advice of an authenticated doctor .  

What to expect when taking Enhertu? 

Enhertu (Fam-trastuzumab deruxtecan-nxki) is given intravenously, which means this medication is typically delivered directly into the bloodstream through an IV or port. Medicine is prescribed every 3 weeks unless the disease grows or unacceptable adverse reactions develop.

Those who are pregnant or want to get pregnant should not use Enhertu. This medicinal product can be responsible for causing embryo death and birth defects. It’s necessary that women don’t get pregnant while on treatment with Enhertu; effective birth control should be considered. 

Is there hair loss with the patients of Enhertu ?

Yes , hair loss is a common side effect faced by the patients of Enhertu 

own country ? 

Yes Indian pharma network  Named Patient program help’s patient to procure the medicines which are not available or approved in one’s own country . Indian pharma network  provides access to Enhertu (Fam-trastuzumab deruxtecan-nxki) Manufactured by: Daiichi Sankyo, Inc., and Marketed by AstraZeneca Pharmaceuticals LP, Wilmington . 

More - Enhertu: Know about Medication